Logo image of STIM

NEURONETICS INC (STIM) Stock Fundamental Analysis

NASDAQ:STIM - US64131A1051 - Common Stock

3.36 USD
-0.02 (-0.59%)
Last: 8/27/2025, 8:19:07 PM
3.38 USD
+0.02 (+0.6%)
Pre-Market: 8/28/2025, 8:00:00 AM
Fundamental Rating

2

Overall STIM gets a fundamental rating of 2 out of 10. We evaluated STIM against 185 industry peers in the Health Care Equipment & Supplies industry. STIM may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, STIM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year STIM has reported negative net income.
In the past year STIM has reported a negative cash flow from operations.
STIM had negative earnings in each of the past 5 years.
In the past 5 years STIM always reported negative operating cash flow.
STIM Yearly Net Income VS EBIT VS OCF VS FCFSTIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

STIM has a worse Return On Assets (-36.24%) than 61.08% of its industry peers.
The Return On Equity of STIM (-179.75%) is worse than 71.89% of its industry peers.
Industry RankSector Rank
ROA -36.24%
ROE -179.75%
ROIC N/A
ROA(3y)-29.62%
ROA(5y)-29.17%
ROE(3y)-103.71%
ROE(5y)-91.08%
ROIC(3y)N/A
ROIC(5y)N/A
STIM Yearly ROA, ROE, ROICSTIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

STIM has a Gross Margin of 56.15%. This is comparable to the rest of the industry: STIM outperforms 52.43% of its industry peers.
STIM's Gross Margin has been stable in the last couple of years.
STIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y-0.84%
STIM Yearly Profit, Operating, Gross MarginsSTIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

2

2. Health

2.1 Basic Checks

STIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STIM has been increased compared to 1 year ago.
Compared to 5 years ago, STIM has more shares outstanding
The debt/assets ratio for STIM has been reduced compared to a year ago.
STIM Yearly Shares OutstandingSTIM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STIM Yearly Total Debt VS Total AssetsSTIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

STIM has an Altman-Z score of -3.12. This is a bad value and indicates that STIM is not financially healthy and even has some risk of bankruptcy.
STIM has a Altman-Z score of -3.12. This is in the lower half of the industry: STIM underperforms 64.32% of its industry peers.
STIM has a Debt/Equity ratio of 2.05. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of STIM (2.05) is worse than 86.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.05
Debt/FCF N/A
Altman-Z -3.12
ROIC/WACCN/A
WACC8.92%
STIM Yearly LT Debt VS Equity VS FCFSTIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 2.02 indicates that STIM has no problem at all paying its short term obligations.
The Current ratio of STIM (2.02) is worse than 63.78% of its industry peers.
A Quick Ratio of 1.84 indicates that STIM should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.84, STIM perfoms like the industry average, outperforming 49.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.84
STIM Yearly Current Assets VS Current LiabilitesSTIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for STIM have decreased by -0.89% in the last year.
The Revenue has grown by 54.18% in the past year. This is a very strong growth!
Measured over the past years, STIM shows a small growth in Revenue. The Revenue has been growing by 3.63% on average per year.
EPS 1Y (TTM)-0.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
Revenue 1Y (TTM)54.18%
Revenue growth 3Y10.63%
Revenue growth 5Y3.63%
Sales Q2Q%131.66%

3.2 Future

Based on estimates for the next years, STIM will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.70% on average per year.
The Revenue is expected to grow by 25.79% on average over the next years. This is a very strong growth
EPS Next Y57.31%
EPS Next 2Y29.23%
EPS Next 3Y21.45%
EPS Next 5Y18.7%
Revenue Next Year109.15%
Revenue Next 2Y52.89%
Revenue Next 3Y38.05%
Revenue Next 5Y25.79%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
STIM Yearly Revenue VS EstimatesSTIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
STIM Yearly EPS VS EstimatesSTIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

STIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year STIM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STIM Price Earnings VS Forward Price EarningsSTIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STIM Per share dataSTIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

STIM's earnings are expected to grow with 21.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.23%
EPS Next 3Y21.45%

More info and screens

0

5. Dividend

5.1 Amount

STIM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEURONETICS INC

NASDAQ:STIM (8/27/2025, 8:19:07 PM)

Premarket: 3.38 +0.02 (+0.6%)

3.36

-0.02 (-0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners25.75%
Inst Owner Change-2.52%
Ins Owners6.41%
Ins Owner Change5.39%
Market Cap222.16M
Analysts82.22
Price Target6.63 (97.32%)
Short Float %13.44%
Short Ratio4.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-78.26%
Min EPS beat(2)-91.81%
Max EPS beat(2)-64.71%
EPS beat(4)0
Avg EPS beat(4)-74.53%
Min EPS beat(4)-91.81%
Max EPS beat(4)-54.06%
EPS beat(8)2
Avg EPS beat(8)-34.91%
EPS beat(12)6
Avg EPS beat(12)-13.79%
EPS beat(16)8
Avg EPS beat(16)-9.34%
Revenue beat(2)2
Avg Revenue beat(2)4.68%
Min Revenue beat(2)1.52%
Max Revenue beat(2)7.85%
Revenue beat(4)3
Avg Revenue beat(4)4.16%
Min Revenue beat(4)-5.05%
Max Revenue beat(4)12.31%
Revenue beat(8)4
Avg Revenue beat(8)0.37%
Revenue beat(12)7
Avg Revenue beat(12)1.37%
Revenue beat(16)10
Avg Revenue beat(16)1.33%
PT rev (1m)-4.88%
PT rev (3m)-4.88%
EPS NQ rev (1m)-90%
EPS NQ rev (3m)24%
EPS NY rev (1m)-60.75%
EPS NY rev (3m)-61.5%
Revenue NQ rev (1m)-1.18%
Revenue NQ rev (3m)59.81%
Revenue NY rev (1m)0.23%
Revenue NY rev (3m)0.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2
P/FCF N/A
P/OCF N/A
P/B 8.18
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS1.68
BVpS0.41
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.24%
ROE -179.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.15%
FCFM N/A
ROA(3y)-29.62%
ROA(5y)-29.17%
ROE(3y)-103.71%
ROE(5y)-91.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y-0.84%
F-Score3
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 2.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.15%
Cap/Sales 0.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 1.84
Altman-Z -3.12
F-Score3
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)129%
Cap/Depr(5y)137.27%
Cap/Sales(3y)3.43%
Cap/Sales(5y)3.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
EPS Next Y57.31%
EPS Next 2Y29.23%
EPS Next 3Y21.45%
EPS Next 5Y18.7%
Revenue 1Y (TTM)54.18%
Revenue growth 3Y10.63%
Revenue growth 5Y3.63%
Sales Q2Q%131.66%
Revenue Next Year109.15%
Revenue Next 2Y52.89%
Revenue Next 3Y38.05%
Revenue Next 5Y25.79%
EBIT growth 1Y-28.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year77.95%
EBIT Next 3Y32.94%
EBIT Next 5Y16.54%
FCF growth 1Y1.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.53%
OCF growth 3YN/A
OCF growth 5YN/A